ProRx Pharma, a health and wellness 503B outsourcing facility, announced on Monday that it has launched four new injectable products -- Sermorelin, NAD+, Glutathione and MIC/B6/B12 -- as part of its expanded health and wellness line.
The new offerings are intended to meet rising demand for preventative treatments among physicians and patients.
Each product is a standalone formulation with its own National Drug Code and Beyond Use Date ranging from 3 to 12 months. Distribution includes bulk shipping to 26 states through partners such as 503A pharmacies, clinics, med spas and telemedicine providers, with direct-to-patient shipping available in all 50 US states.
The newly introduced compounds serve various functions: Sermorelin is a growth hormone peptide, NAD+ is a cellular antioxidant, Glutathione functions as an antioxidant and MIC/B6/B12 is a lipotropic amino acid complex.
This product launch follows ProRx Pharma's February expansion, which doubled its operational footprint to 6,888 sq ft. The facility upgrade has tripled manufacturing capacity and improved compliance capabilities aligned with FDA and compounding lab standards.
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
ProRx Pharma expands wellness portfolio with launch of four preventative injectables
ResVita Bio's RVB-003 receives US FDA Orphan Drug Designation
Tasman Therapeutics to raise USD175m in Series A funding
Variant's VAR002 receives positive European regulatory feedback
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
Hoth Therapeutics partners with Washington University to advance Alzheimer's disease research
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Amygdala Neurosciences selects ANS-858 as lead clinical candidate for substance use disorder
Quest Diagnostics expands HPV self-collection screening option